Company / Depreciation & Amortization
SUTRO BIOPHARMA, INC. Depreciation & Amortization History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$7.2M
FY2025
5-year range
$4.3M / $7.2M
FY2021-FY2025
Trend
+26.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Depreciation & Amortization has increased for 3 consecutive years, from $4M in FY2022 to $7M in FY2025.
Based on SEC 10-K filings.
$7M in FY2025 with a 5-year CAGR of +9.7%.
Increased from $5M to $7M over the past 2 years.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +18.9%
- 5-Year CAGR
- +9.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- SUTRO BIOPHARMA, INC.'s depreciation & amortization has grown for 3 consecutive years.
- 5-year CAGR of +9.7%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 26.9% year-over-year.
- Lowest depreciation & amortization in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -3.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.2M | +26.9% |
| FY2024 | $5.7M | +17.5% |
| FY2023 | $4.8M | +12.7% |
| FY2022 | $4.3M | -10.0% |
| FY2021 | $4.8M | +5.2% |
| FY2020 | $4.5M | -9.0% |
| FY2019 | $5.0M | -11.9% |
| FY2018 | $5.7M | - |
As of FY2025 · SEC 10-K Annual Filings · Last checked Jun 28, 2026